文献速递甲状腺疾病

结合超声成像与分子检测的多模态深度学习模型用于不确定甲状腺结节的风险分层

Combining Ultrasound Imaging and Molecular Testing in a Multimodal Deep Learning Model for Risk Stratification of Indeterminate Thyroid Nodules.
PubMed 文献 · Thyroid · 2025-04-21

该研究回顾性分析2016至2022年UCLA医学中心333例不确定甲状腺结节患者,构建整合超声图像与分子检测的多模态深度学习模型。相比临床基线(Bethesda细胞学+分子检测),集成模型将AUROC从0.728提升至0.831,PPV从0.448提升至0.477,特异性从0.664提升至0.703,敏感度维持0.946,差异有统计学意义(p=0.0008)。

要点

  • 多模态模型较临床基线显著提高PPV和特异性,敏感度保持0.946。
  • 临床基线AUROC为0.728,集成模型AUROC为0.831,差异有统计学意义(p=0.0008)。
  • 作者认为该框架可减少不确定结节患者的良性甲状腺切除。

核心结论

  • 多模态模型通过显著提高PPV和特异性并维持高敏感度,增强了分子检测的性能。
  • 作者认为该框架可用于减少不确定结节患者的良性甲状腺切除。

研究设计与样本

  • 回顾性分析2016至2022年UCLA医学中心333例不确定甲状腺结节患者(259例良性,74例恶性)。
  • 评估四种配置:全帧超声图像、256×256图像块、128×128图像块及前三者组合的集成模型。
  • 临床基线由Bethesda细胞学和分子检测结果构成,模型采用按手术结局分层的五折交叉验证评估。

主要发现

  • 临床基线(Bethesda+分子检测)AUROC为0.728 [0.68, 0.78],敏感度0.946 [0.88, 1.00],特异性0.664 [0.60, 0.73],PPV为0.448 [0.41, 0.48]。
  • 集成模型AUROC为0.831 [0.77, 0.89],敏感度0.946 [0.88, 1.00],特异性0.703 [0.66, 0.75],PPV为0.477 [0.46, 0.50]。
  • 集成模型较临床基线的改善有统计学意义(p=0.0008)。

局限性

  • 本研究受限于单中心数据集。
  • 缺乏外部验证。
  • 使用二值化分子检测输出而非细粒度恶性风险概率。
  • 未来工作应在多样人群和更大外部数据集中验证这些发现,以实现更全面的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: Indeterminate cytology (Bethesda III and IV) represents 15-30% of biopsied thyroid nodules and require additional diagnostic testing. Molecular testing (MT) is a commonly used diagnostic tool that evaluatesmalignancy risk through next generation sequencing of fine needle aspiration (FNA) samples. While MT achieves high sensitivity (97-100%) in ruling out malignancy, its specificity and positive predictive value (PPV) remain relatively low. This study proposes a multimodal deep learning model that integrates ultrasound (US) imaging with MT to improve risk stratification by enhancing PPV while maintaining high sensitivity. Combining these modalities leverages complementary information from both molecular and imaging data, addressing limitations in current approaches and offering a robust framework for evaluating indeterminate nodules. Methods: We retrospectively analyzed 333 patients with indeterminate thyroid nodules (259 benign, 74 malignant) at UCLA Medical Center between 2016 and 2022. We evaluated four configurations: whole frame US images, 256 × 256 patches, 128 × 128 patches, and an ensemble model combining the first three configurations. The clinical baseline consisted of Bethesda cytology and MT results. Models were assessed using five fold cross validation stratified by surgical outcomes. Results: The clinical baseline (Bethesda + MT) achieved an AUROC of 0.728 [0.68, 0.78] with sensitivity of 0.946 [0.88, 1.00], specificity of 0.664 [0.60, 0.73], and PPV of 0.448 [0.41, 0.48]. The proposed ensemble model demonstrated improved performance, achieving an AUROC of 0.831 [0.77, 0.89] with a sensitivity of 0.946 [0.88, 1.00], specificity of 0.703 [0.66, 0.75], and PPV of 0.477 [0.46, 0.50]. These improvements were statistically significant (p = 0.0008). Conclusion: Our multimodal model enhances MT performance by providing statistically significant improvements in PPV and specificity while maintaining high sensitivity. Our framework could be leveraged to reduce the number of benign thyroid resections in patients with indeterminate nodules. However, this study is limited by its single center dataset, lack of external validation, and the use of binarized MT outputs rather than granular malignancy risk probabilities. Future work should validate these findings across diverse populations and larger external datasets for more comprehensive risk stratification.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Athreya S, Melehy A, Suthahar SSA, et al. Combining Ultrasound Imaging and Molecular Testing in a Multimodal Deep Learning Model for Risk Stratification of Indeterminate Thyroid Nodules. Thyroid. 2025. PMID: 40256961. doi:10.1089/thy.2024.0584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。